1. Nimer SD: Essential thrombocythaemia: Another "heterogenous disease" better understood. Blood 93:415-416, 1999.

2. Lengfelder E, Hochhaus A, Kronawitter U, Höche D, Queisser W, Jahn-Elder M, Burkhardt R, Reiter A, Ansari H, Hehlmann R: Should a platelet limit of 600 X 109/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 100:15-23, 1998.

3. Messinezy M, MacDonald LM, Nunan TO, Westwood NB, Chinn S, Pearson TC: Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: Comparison with SPECT. Br J Haematol 98:103-107, 1997.

4. Messinezy M, Westwood N, Sawyer B, Grace R, Holland LJ, Lawrie AS, Pearson TC: Primary thrombocythaemia: A composite approach to diagnosis. Clin Lab Haematol 16:139-148, 1994.

5. Briere J, Kiladjian J-J, Peynaud-Debayle E: Megakaryocytes and platelets in myeloproliferative disorders. Baillieres Clin Haematol 10:65-88, 1997.

6. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, Machin SJ, Linch DC: Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol 107: 139-147, 1999.

7. Westwood NB, Pearson TC: Diagnostic applications of haemopoi-etic progenitor culture techniques in polycythaemias and throm-bocythaemias. Leuk Lymphoma. 22(Suppl 1):95-103, 1996.

8. Murphy S, Peterson P, Iland H, Laszlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39, 1997.

9. Champion KM, Gilbert JGR, Asimakopoulos FA, Hinshelwood S, Green AR: Clonal haemopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 75:920-926, 1997.

10. Gale RE, Fielding AK, Harrison CN, Linch DC: Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the eld erly suggests stochastic clonal loss with age. Br J Haematol 98:512-519, 1997.

11. Georgii A, Buesche G, Kreft A: The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 11:721-749, 1998.

12. Thiele J, Kvasnicka HM, Zankovich R, Diehl V: Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 85:1126-1134, 2000.

13. Carneskog J, Kutti J, Wadenvik H, Lundberg P-A, Lindstedt G: Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 60:278-282, 1998.

14. Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GF: Myelofibrosis in primary myelodysplastic syndromes: A clin-ico-morphological study of 10 cases. Br J Haematol 71:499-504, 1989.

15. Boultwood J, Lewis S, Wainscoat JS: The 5q- syndrome. Blood 84:3253-3260, 1994.

16. Van Genderen PJJ, Mulder PGH, Waleboer M, van de Moesdijk D, Michiels JJ: Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin. Br J Haematol 97:179-184, 1997.

17. Barbui T, Finazzi G, Dupuy E, Kiladjian J-J, Briere J: Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centres. Leuk Lymphoma 22(Suppl. 1):149-160, 1996.

18. Sterkers Y, Preudhomme C, Lai J-L, Demory J-L, Caulier M-T, Wat-tel E, Bordessoule D, Bauters F, Fenaux P: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91:616-622, 1998.

19. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.

20. Lengfelder E, Griesshammer M, Hehlmann R: Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22 (Suppl. 1):135-142, 1996.

21. Silverstein MN, Petrone ME, Petitt RM, Dement MP, Vukovich RA: The safety profile of anagrelide for treatment of thrombocythemia. Blood. 88:583a, 1996.

22. Van de Pette JEW, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G: Primary thrombocythaemia treated with busul-phan. Br J Haematol, 62:229-237, 1986.

23. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long term follow up ofa randomized clinical trial. Br J Haematol 110:577-583, 2000.

24. Griesshammer M, Heimpel H, Pearson TC: Essential thrombo-cythaemia and pregnancy. Leuk Lymphoma 22(Suppl. 1):57-63, 1996.

25. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, Petti MC, Pogliani E, Ricetti M, Rupoli S, Visani G, Tura S: The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 104:730-737, 1999.

26. Reilly JT: Pathogenesis of idiopathic myelofibrosis: A review. Hematology 3:205-213, 1998.

27. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88:1013-1018, 1996.

28. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Wat-more A, Potter A: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol 98:96-102, 1997.

29. Cervantes F, Barosi G, Demory J-L, Reilly JT, Guarnone R, Dupriez B, Pereira A, Montserrat E: Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk-groups. Br J Haematol 102:684-690, 1998.

30. Altura RA, Head DR, Wang WC: Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol 109:459-462, 2000.

31. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcesse W, Bacigalupo A, Przepiorka D, O'Donnell MR, Polchi P, Buzyn A, Sutton L, Cazals-Hatem D, Sale G, de Witte T, Deeg J, Gluckman E: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Center Collaborative Study. Blood 93:2831-2838, 1999.

32. Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das Gupta E, Russell NH: Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: Evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol 108:430-433, 2000.

33. Anderson JE, Deeg HJ, Tefferi A, Craig F, Guardiola P, Gazitt Y, Razvilla B, Alsina M, Callander N, Freytes C, Tsai T: Effective treatment of myelofibrosis by autologous peripheral blood stem cell transplantation. Blood 94:396a, 1999.

34. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN: Splenectomy in myelofibrosis with myeloid metaplasia: A single institution experience with 223 patients. Blood 95:2226-2233, 2000.

35. Elliot MA, Tefferi A: Splenic irradiation in myelofibrosis with myloid metaplasia: A review. Blood Rev 13:163-170, 1999.

36. Reilly JT: Pathogenesis and management of idiopathic myelofibrosis. Ballieres Clin Haematol 11:751-767, 1999.

37. Reilly JT, Nash JRG, Mackie MJ, McVerry BA: Endothelial cell proliferation in myelofibrosis. Br J Haematol 60:625-630, 1985.

38. Barosi G, Grossi A, Comotti B, Marchetti M: Thalidomide in patients with myelofibrosis with myeloid metaplasia. Blood 96:746a, 2000.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment